Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Orelabrutinib Could be ‘Preferred’ BTK Inhibitor for MCL

Key clinical point: Orelabrutinib, a novel Bruton tyrosine kinase inhibitor, appears safe and effective in patients with relapsed or refractory mantle cell lymphoma.

Major finding: Orelabrutinib produced an overall response rate of 86% and a 12-month progression-free survival rate of 64%.

Study details: A phase 2 trial of 106 patients with relapsed/refractory mantle cell lymphoma.

Disclosures: The study was sponsored by InnoCare Pharma. Dr. Deng reported having no conflicts of interest.


Deng L et al. ASH 2019, Abstract 755.